Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility
about
Structural basis of HIV-1 resistance to AZT by excisionSelection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidineCoresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase.3'-Azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants.A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidineN348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistanceZidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptaseEstimating HIV-1 fitness characteristics from cross-sectional genotype dataA recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors.Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistanceClinically relevant genotype interpretation of resistance to didanosineConvergent evolution of reverse transcriptase (RT) genes of human immunodeficiency virus type 1 subtypes E and B following nucleoside analogue RT inhibitor therapies.High-level resistance to 3'-azido-3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assayShift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase.The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition.HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Impaired replication capacity of acute/early viruses in persons who become HIV controllers.Mutagenically separated PCR assay for rapid detection of M41L and K70R zidovudine resistance mutations in CRF01_AE (subtype E) human immunodeficiency virus type 1.Frequency of mutations conferring resistance to nucleoside reverse transcriptase inhibitors in human immunodeficiency virus type 1-infected patients in Korea.Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.Fluorescent dye terminator sequencing methods for quantitative determination of replication fitness of human immunodeficiency virus type 1 containing the codon 74 and 184 mutations in reverse transcriptase.Silent mutations at codons 65 and 66 in reverse transcriptase alleviate indel formation and restore fitness in subtype B HIV-1 containing D67N and K70R drug resistance mutations.A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.HIV-1 antiretroviral drug therapy.Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation.Transmission of human immunodeficiency virus I drug resistance - a case report. What are the clinical implications?Analysis of the Zidovudine Resistance Mutations T215Y, M41L, and L210W in HIV-1 Reverse Transcriptase.Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3'-azido, 3'-deoxythymidine: a QSAR investigation.The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility.Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184VBiochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine.Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.
P2860
Q24596976-C95A9A98-6A94-483C-AC42-8E222B3B3961Q28344137-E2103DF1-B3F1-43C2-89D9-A38130A52E37Q28369167-1125CED8-EA22-4424-B0A1-A9699ECF8C1AQ28379497-77820B9F-76A1-4FE0-A958-1767FE080FB0Q28379499-DC7E6739-CEDE-421D-AAA2-8C81D0179152Q28471689-3D067609-1300-4DC7-82D2-0BC7A9079B93Q28481004-C2FE9323-30D5-4F49-95E1-1C8F7199E81DQ28544753-750BC3F0-03DF-4F16-BF87-02DA0FDA2E28Q32157822-96CAF535-8C76-46F5-90B5-45D448BD2111Q33667350-9F3A14E1-EB83-40B9-994C-5D434897A6BEQ33770146-7B5729BE-2197-44E7-97AF-283BFAD8D0DAQ33787173-D9DC2B08-5814-44B4-99B5-78027337C3BCQ33796791-A27289F3-FC28-4DC0-8AF5-C94CA70E726CQ33814927-AC8038FC-6DC9-42A1-ADF2-7D7A16AD5423Q33815285-C2987E48-5482-41EA-8C29-630B0B8D0B4FQ33826453-1BE4F366-FCAB-44F0-9F5B-884D5FAA3902Q33841974-32957D82-17F4-43BE-A529-2B126F122313Q33889635-FC48C2A8-D8D0-44BE-8B9D-1AB192CC2900Q33896402-D3A60ABF-282F-4CE4-9CB3-49D9FB713ED1Q33900459-6A7845A0-7A7E-481E-90EA-65F72A2B5823Q33906239-EB4AEB85-B964-4914-B1A6-83E14E1507ECQ33963989-555E1A27-1C5F-4148-89DE-9AB0D89252E6Q34252835-E230B877-7361-4616-810C-EE5503B3BC72Q34454702-97F77937-E101-4CC5-9C64-D9C500AC9A26Q34717892-AAA85A93-2851-4AE5-8911-608047019A2DQ35156768-AA297CC1-3997-459C-850F-946C14AA06FEQ35237036-E439FEAB-9B60-48B4-A462-348A5129B7B2Q35742512-CB72A9DD-E068-4FE2-BD9F-603BC8327C48Q35853012-65E58BCD-79A3-4CE6-9D13-0CE2B3C20F68Q35899105-E13CAF51-4236-45F9-9721-25D9EBBF03A5Q35959266-E34D60FB-F620-4343-B8BC-250986AA6BB4Q36290768-8B2A395F-A5F2-4C43-99A4-C157EB5517F5Q36981369-4B119544-2E64-4578-8432-EDB3D04955D8Q37018369-FEBD4C66-8A51-452C-A447-A1403781F3B0Q37256719-E2E511E1-3AF1-489C-842E-1FEB5E9D8CBCQ39142877-508B9910-BF9B-43DE-AF57-5FAADDA6C354Q39471491-58B81D8A-981F-4560-A018-20F079C63AD7Q39473036-79F39F6B-353B-4C7C-A7FA-93056139E707Q39477865-9A2485DB-35A7-4F5C-A683-227B76054B78Q39550343-198E6997-0C93-45EA-9C30-EBDF56C97868
P2860
Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility
description
1996 nî lūn-bûn
@nan
1996 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Significance of amino acid var ...... for zidovudine susceptibility
@ast
Significance of amino acid var ...... for zidovudine susceptibility
@en
Significance of amino acid var ...... for zidovudine susceptibility
@nl
type
label
Significance of amino acid var ...... for zidovudine susceptibility
@ast
Significance of amino acid var ...... for zidovudine susceptibility
@en
Significance of amino acid var ...... for zidovudine susceptibility
@nl
prefLabel
Significance of amino acid var ...... for zidovudine susceptibility
@ast
Significance of amino acid var ...... for zidovudine susceptibility
@en
Significance of amino acid var ...... for zidovudine susceptibility
@nl
P2093
P2860
P1433
P1476
Significance of amino acid var ...... for zidovudine susceptibility
@en
P2093
B A Larder
I Kinghorn
P R Harrigan
P2860
P304
P407
P577
1996-09-01T00:00:00Z